Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A method and system for order management that allows access to additional pools of liquidity is described. Other embodiments are also described.

Abstract: A method and system for determining the presence of a selected analyte in a sample include an all-dielectric, metasurface sensor having one or more arrays of subwavelength-scale, dielectric nanopillars having anisotropic cross-sections. Nanopillars in selected regions of the metasurface sensor may be functionalized with binders for selectively binding the selected analyte. Methods for detecting the selected analyte in a sample rely on exposing the sensor to a test sample, probing the sensor with probe light having a selected polarization state, and comparing the polarization state of output light reflected or transmitted by functionalized regions of the sensor with a baseline polarization state of output light determined with a sample lacking the selected analyte.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Abstract: A robotic mower navigation system includes a plurality of sensors on a robotic mower that detect strength and polarity of a magnetic field from an electric current through a boundary wire. An electronic control unit receives data concerning the magnetic field from the plurality of sensors as the robotic mower follows the boundary wire, tracks the data provided by the sensors, compares the data with a reference pattern that defines at least one specified feature of the boundary wire, and provides commands to the robotic mower based on the comparison. The electronic control unit may command the robotic mower to follow a second boundary wire to a remotely located charging station instead of the first boundary wire based on detected features of the boundary wire such as sharp corners or crossings.

Abstract: A robotic mower navigation system includes a plurality of sensors on a robotic mower that detect strength and polarity of a magnetic field from an electric current through a boundary wire. An electronic control unit receives data concerning the magnetic field from the plurality of sensors as the robotic mower follows the boundary wire, tracks the data provided by the sensors, compares the data with a reference pattern that defines at least one specified feature of the boundary wire, and provides commands to the robotic mower based on the comparison. The electronic control unit may command the robotic mower to follow a second boundary wire to a remotely located charging station instead of the first boundary wire based on detected features of the boundary wire such as sharp corners or crossings.

Abstract: An anesthetic cartridge is adapted to receive a volume of buffer by displacing a plunger in one end of the anesthetic cartridge inwardly so that addition of the buffer volume will not displace the plunger excessively beyond the end of the cartridge body. The inwardly displaced end is protected by a plug or cover which prevents contamination and which is ejected when the buffer is added. The amount of buffer volume injected is selected to raise the pH of the anesthetic to a target value and to simultaneously achieve a target tonicity.

Abstract: Anesthetics and other medical solutions are stored in a cartridge including a hollow body having a needle-penetrable septum at one end and a plunger at another end. A protective plug is inserted into the open plunger end of the cartridge and protects the cartridge from contamination per use. A buffer or other material may be injected into the cartridge, causing displacement of the protective plug, allowing the cartridge to then be used in a syringe or other delivery system. The anesthetic may contain at least one solute and have an initial tonicity and an initial pH. A volume of buffer may be injected through the septum into the anesthetic, where the initial solute concentration and initial pH of the anesthetic may be selected to provide a target pH and target tonicity after the buffer is introduced.

Abstract: Implantable prosthetic valve systems and methods for implanting them are provided. Magnets are employed within one or more components of the valve systems to facilitate anchoring of the prosthetic valve at a target implant site, delivery of the prosthetic valve to the target implant site or both.

Abstract: Anastomotic components may be attached to hollow bodies or vessels by magnetic or mechanical force to create an anastomosis, form a port in a vessel, or repair a diseased vessel lumen. Anastomoses are created by coupling a first connection to an end of a vessel and then attracting it to a second connector secured to the side wall of another vessel. The connection between the first and second connectors may be solidly magnetic, solely mechanical, or a combination thereof. Also disclosed are methods and devices for treating diseased vessel lumens, for example abdominal aortic aneurysm. A plurality of docking members is attached to the vessel at solicited positions, and then one or more grafts is secured to the docking members in any suitable manner.

Abstract: Devices and methods for delivering conduits into the wall of a patient's heart to communicate a coronary vessel with a heart chamber. The devices are passed through the coronary vessel and the heart wall to place the conduit and establish a blood flow path between the vessel and the heart chamber. Additional devices and methods are provided for removing tissue from a coronary vessel or the heart wall to establish a flow path between the coronary vessel in communication with the heart chamber.

Abstract: Implantable prosthetic valve systems and methods for implanting them are provided. Magnets are employed within one or more components of the valve systems to facilitate anchoring of the prosthetic valve at a target implant site, delivery of the prosthetic valve to the target implant site or both.

Abstract: Implantable prosthetic valve systems and methods for implanting them are provided. Magnets are employed within one or more components of the valve systems to facilitate anchoring of the prosthetic valve at a target implant site, delivery of the prosthetic valve to the target implant site or both.

Abstract: Anastomotic components may be attached to hollow bodies or vessels by magnetic or mechanical force to create an anastomosis, form a port in a vessel, or repair a diseased vessel lumen. Anastomoses are created by coupling a first connection to an end of a vessel and then attracting it to a second connector secured to the side wall of another vessel. The connection between the first and second connectors may be solidly magnetic, solely mechanical, or a combination thereof. Also disclosed are methods and devices for treating diseased vessel lumens, for example abdominal aortic aneurysm. A plurality of docking members is attached to the vessel at solicited positions, and then one or more grafts is secured to the docking members in any suitable manner.